| Trial ID: | L3683 |
| Source ID: | NCT01990469
|
| Associated Drug: |
Gemigliptin
|
| Title: |
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM
|
| Interventions: |
DRUG: Gemigliptin|DRUG: Gemigliptin placebo
|
| Outcome Measures: |
Primary: Change of HbAlc from baseline at Week 24, 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: LG Life Sciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
219
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-01
|
| Completion Date: |
2015-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-04-19
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01990469
|
